indication directory

Major Depressive Disorder clinical trial intelligence

Trials are included only when the source condition or controlled indication mapping directly matches this disease area. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

indication

Association rule

source condition

NCT04043533

Source recordAI-normalized

The Effect of an Exercise Program in Reducing the Severity of Postpartum Depression in Women: A Randomized Control Trial

The study investigates the effectiveness of an exercise program in alleviating postpartum depression among women in Turkey. Given the reported prevalence of 23.8% for postpartum depression in the region, there is a significant market opportunity for non-pharmacological interventions that can be integrated into maternal healthcare. The findings could support the development of exercise-based therapeutic programs, potentially leading to partnerships with healthcare providers and wellness organizations focused on maternal mental health. Competitive implications include positioning against pharmacological treatments and other behavioral therapies, emphasizing the cost-effectiveness and accessibility of exercise interventions.

AI analysis

Indication: Depression, Postpartum

Modality: behavioral intervention

Target: Postpartum Depression (PPD) severity reduction through exercise intervention.

Sponsor: Didem Kucukkelepce

Source URL: ClinicalTrials.gov

Source updated: Aug 02, 2019

Ingested: Jun 12, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Depression, Postpartum

View original source fields

Condition raw: Depression, Postpartum

Condition normalized: Depression, Postpartum

Modality raw: behavioral intervention

Modality normalized: behavioral intervention

Target raw: Postpartum Depression (PPD) severity reduction through exercise intervention.

Target normalized: Postpartum Depression (PPD) severity reduction through exercise intervention.

Open report

NCT00965497

Source recordAI-normalized

An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (Lexapro®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis

Escitalopram (Lexapro) is being evaluated for its efficacy in treating major depressive disorder in patients with comorbid Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Given the increasing recognition of mental health issues in chronic neurological conditions, this study addresses an unmet need in the market. The potential to expand Lexapro's indications could enhance its market position against competitors in the antidepressant space, particularly those targeting similar patient populations. The results may influence prescribing practices and reimbursement policies, thereby impacting market access and commercial strategy for the product.

AI analysis

Indication: Major Depression

Modality: small molecule

Target: Selective serotonin reuptake inhibitor (SSRI) mechanism targeting serotonin transporters.

Sponsor: University of South Carolina

Source URL: ClinicalTrials.gov

Source updated: May 01, 2019

Ingested: Jun 09, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Major Depression

View original source fields

Condition raw: Major Depression, Multiple Sclerosis, Amyotrophic Lateral Sclerosis

Condition normalized: Major Depression, Multiple Sclerosis, Amyotrophic Lateral Sclerosis

Modality raw: small molecule

Modality normalized: small molecule

Target raw: Selective serotonin reuptake inhibitor (SSRI) mechanism targeting serotonin transporters.

Target normalized: Selective serotonin reuptake inhibitor (SSRI) mechanism targeting serotonin transporters.

Open report

NCT01263223

Source recordAI-normalized

Effect of LY2216684 on Ambulatory Heart Rate and Blood Pressure in Patients With Major Depressive Disorder Who Are Being Treated With Selective Serotonin Reuptake Inhibitors

Effect of LY2216684 on Ambulatory Heart Rate and Blood Pressure in Patients With Major Depressive Disorder Who Are Being Treated With Selective Serotonin Reuptake Inhibitors is a PHASE1 clinical asset sponsored by Eli Lilly and Company in Major Depressive Disorder. SEO and diligence focus: LY2216684, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI analysis

Indication: Major Depressive Disorder

Modality: small molecule

Target: LY2216684, Placebo

Sponsor: Eli Lilly and Company

Source URL: ClinicalTrials.gov

Source updated: Oct 23, 2018

Ingested: May 23, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Major Depressive Disorder

View original source fields

Condition raw: Major Depressive Disorder

Condition normalized: Major Depressive Disorder

Modality raw: major depressive disorder

Modality normalized: small molecule

Target raw: LY2216684, Placebo

Target normalized: LY2216684, Placebo

Open report

NCT02475954

Source recordAI-normalized

Telehealth Cognitive-Behavioral Therapy for Depression in Parkinson's Disease

Telehealth Cognitive-Behavioral Therapy for Depression in Parkinson's Disease is a NA clinical asset sponsored by VA Office of Research and Development in Depression, Parkinson's Disease. SEO and diligence focus: TH-CBT, Standard Care, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI analysis

Indication: Depression

Modality: behavioral intervention

Target: TH-CBT, Standard Care

Sponsor: VA Office of Research and Development

Source URL: ClinicalTrials.gov

Source updated: Jul 28, 2023

Ingested: May 23, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Depression

View original source fields

Condition raw: Depression

Condition normalized: Depression

Modality raw: Parkinson disease

Modality normalized: behavioral intervention

Target raw: TH-CBT, Standard Care

Target normalized: TH-CBT, Standard Care

Open report